Skip to content
2000
Volume 31, Issue 13
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867330666230324152532
2024-04-01
2025-07-10
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867330666230324152532
Loading

  • Article Type:
    Review Article
Keyword(s): cancer immunotherapy; CD155; immune checkpoint inhibitor; PD-1; TIGIT; tumor cells
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test